- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00721617
FFA Hypertension and Inflammation in Lean and Obese Subjects (FFAADA)
Free Fatty Acids-Induced Hypertension, Endothelial Dysfunction, Inflammation, Insulin Resistance, and Autonomic Dysfunction in Lean and Obese Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30303
- Grady Memorial Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males or females
- Obese subjects (body mass index (BMI) ≥ 30 kg/m^2)
- 18 and 65 years
- Blood pressure reading < 140/80 mm Hg and no prior history of hypertension
Exclusion Criteria:
- History of diabetes mellitus
- History of hypertension
- Fasting triglyceride levels > 250 mg/dL
- Liver disease (ALT 2.5x > upper limit of normal)
- Serum creatinine ≥1.5 mg/dL
- Smokers, drug or alcohol abuse
- Mental condition rendering the subject unable to understand the scope and possible consequences of the study
- Female subjects who are pregnant or breast feeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Obese subjects
Obese normotensive subjects will receive 24 hour challenges on 3 separate occasions, in a random order, with IV Normal Saline at 20ml/hour, IV Intralipid (20% solution at 20 ml/hour and an oral fat load (96g/24 hours)
|
Lean and obese normotensive subjects will receive Intralipid 20% infusion.
Intralipid is an oil-in-water emulsion derived from egg phospholipids, soybean, and glycerol.
The Intralipid 20% long-chain triglyceride emulsion contains: 200 g of soy bean oil; 12 g of egg yolk; 25 g of glycerol.
The emulsion is composed of the following free fatty acids (FFAs): linoleic acid: 50%, oleic acid: 26%, palmitic acid: 10%, stearic acid: 9%, egg yolk, phospholipids: 3.5% It will be given intravenously at 20 ml/hr (96 g/24 h) for 24 hours.
Lean and obese normotensive subjects will receive normal saline at 20 ml/hr for 24 hours.
Lean and obese normotensive subjects will receive an oral fat load at 96 g/24hr.
The oral liquid fat load will be given in equal amounts (16 g) every 4 hours (total 96 g over 24 hours).
|
Active Comparator: Lean subjects
Lean normotensive subjects will receive 24 hour challenges on 3 separate occasions, in a random order, with IV Normal Saline at 20ml/hour, IV Intralipid (20% solution at 20 ml/hour and an oral fat load (96g/24 hours)
|
Lean and obese normotensive subjects will receive Intralipid 20% infusion.
Intralipid is an oil-in-water emulsion derived from egg phospholipids, soybean, and glycerol.
The Intralipid 20% long-chain triglyceride emulsion contains: 200 g of soy bean oil; 12 g of egg yolk; 25 g of glycerol.
The emulsion is composed of the following free fatty acids (FFAs): linoleic acid: 50%, oleic acid: 26%, palmitic acid: 10%, stearic acid: 9%, egg yolk, phospholipids: 3.5% It will be given intravenously at 20 ml/hr (96 g/24 h) for 24 hours.
Lean and obese normotensive subjects will receive normal saline at 20 ml/hr for 24 hours.
Lean and obese normotensive subjects will receive an oral fat load at 96 g/24hr.
The oral liquid fat load will be given in equal amounts (16 g) every 4 hours (total 96 g over 24 hours).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Flow-mediated Dilation From Baseline to 4 Hours
Time Frame: Baseline, 4 hours
|
Endothelium-dependent brachial artery flow-mediated dilation (FMD) was assessed.
Ultrasound images of the brachial artery were obtained and arterial diameters were measured with customized software.
FMD is expressed as the change in diameter from baseline to 4 hours.
|
Baseline, 4 hours
|
Change in Systolic Blood Pressure From Baseline to 4 Hours
Time Frame: Baseline, 4 hours
|
Systolic blood pressure is the amount of pressure the heart generates when pumping blood through the arteries to the body.
Current guidelines identify normal systolic blood pressure as lower than 120 mmHg.
Blood pressure was measured in triplicate with a manual cuff prior to and every 4 hours during the 8 hour infusion with subjects in supine position.
Change is the difference between 4 hour systolic blood pressure from baseline systolic blood pressure.
|
Baseline, 4 hours
|
Change in Systolic Blood Pressure From Baseline to 8 Hours
Time Frame: Baseline, 8 hours
|
Systolic blood pressure is the amount of pressure your heart generates when pumping blood through your arteries to the rest of your body.
Current guidelines identify normal systolic blood pressure as lower than 120 mmHg.
Blood pressure was measured in triplicate with a manual cuff prior to and every 4 hours during the 8 hour infusion with subjects in supine position.
Change is the difference between 8 hour systolic blood pressure from baseline systolic blood pressure.
|
Baseline, 8 hours
|
Change in Diastolic Blood Pressure From Baseline to 4 Hours
Time Frame: Baseline, 4 hours
|
Diastolic blood pressure is the amount of pressure in your arteries when your heart is at rest between beats.
Current guidelines identify normal diastolic blood pressure as lower than 80 mmHg.
Blood pressure was measured in triplicate with a manual cuff prior to and every 4 hours during the 8 hour infusion with subjects in supine position.
Change is the difference between 4 hour diastolic blood pressure from baseline diastolic blood pressure.
|
Baseline, 4 hours
|
Change in Diastolic Blood Pressure From Baseline to 8 Hours
Time Frame: Baseline, 8 hours
|
Diastolic blood pressure is the amount of pressure in your arteries when your heart is at rest between beats.
Current guidelines identify normal diastolic blood pressure as lower than 80 mmHg.
Blood pressure was measured in triplicate with a manual cuff prior to and every 4 hours during the 8 hour infusion with subjects in supine position.
Change is the difference between 8 hour diastolic blood pressure from baseline diastolic blood pressure.
|
Baseline, 8 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in FFA (Free Fatty Acid) Levels From Baseline to 4 Hours
Time Frame: Baseline, 4 hours
|
Blood samples were collected for measurement of free fatty acids (FFA) at baseline and 4 hours after each infusion.
FFA levels were determined by colorimetric method.
Current guidelines identify normal range of FFA level as less than 0.72 mmol/L.
Elevated plasma levels of FFA indicate a greater rate of insulin resistance.
Change is the difference between 4 hour FFA levels from baseline FFA levels.
|
Baseline, 4 hours
|
Changes in FFA (Free Fatty Acid) Levels From Baseline to 8 Hours
Time Frame: Baseline, 8 hours
|
Blood samples were collected for measurement of free fatty acids (FFA) at baseline and 8 hours after each infusion.
FFA levels were determined by colorimetric method.
Current guidelines identify normal range of FFA level as less than 0.72 mmol/L.
Elevated plasma levels of FFA indicate a greater rate of insulin resistance.
Change iis the difference between 8 hour FFA levels from baseline FFA levels.
|
Baseline, 8 hours
|
Change in Triglyceride Levels From Baseline to 4 Hours
Time Frame: Baseline, 4 hours
|
Blood samples were collected for measurement of triglycerides at baseline and 4 hours after each infusion.
Triglyceride levels were measured on CX7 Chemistry Analyzer.
Current guidelines identify normal range of triglyceride level as less than 150 mg/dL.
Elevated levels of triglycerides are associated with an increased risk of developing heart disease.
Change is the difference between 4 hour triglyceride levels from baseline triglyceride levels.
|
Baseline, 4 hours
|
Change in Triglyceride Levels From Baseline to 8 Hours
Time Frame: Baseline, 8 hours
|
Blood samples were collected for measurement of triglycerides at baseline and 4 hours after each infusion.
Triglyceride levels were measured on CX7 Chemistry Analyzer.
Current guidelines identify normal range of triglyceride level as less than 150 mg/dL.
Elevated levels of triglycerides are associated with an increased risk of developing heart disease.
Change is the difference between 8 hour triglyceride levels from baseline triglyceride levels.
|
Baseline, 8 hours
|
Plasma Glucose Levels for Saline Infusion
Time Frame: Baseline, 4 hours, 8 hours
|
Blood samples were collected for measurement of plasma glucose levels at baseline, 4 hours after saline infusion, and 8 hours after saline infusion.
Plasma glucose was measured on CX7 Chemistry Analyzer.
Current guidelines identify normal fasting glucose as less than 100 mg/dL.
High levels of glucose most frequently indicates diabetes.
|
Baseline, 4 hours, 8 hours
|
Plasma Glucose Levels for Intralipid Infusion
Time Frame: Baseline, 4 hours, 8 hours
|
Blood samples were collected for measurement of plasma glucose levels at baseline, 4 hours after intralipid infusion, and 8 hours after intralipid infusion.
Plasma glucose was measured on CX7 Chemistry Analyzer.
Current guidelines identify normal fasting glucose as less than 100 mg/dL.
High levels of glucose most frequently indicates diabetes.
|
Baseline, 4 hours, 8 hours
|
Plasma Glucose Levels for Dextrose Infusion
Time Frame: Baseline, 4 hours, 8 hours
|
Blood samples were collected for measurement of plasma glucose levels at baseline, 4 hours after dextrose infusion, and 8 hours after dextrose infusion.
Plasma glucose was measured on CX7 Chemistry Analyzer.
Current guidelines identify normal fasting glucose as less than 100 mg/dL.
High levels of glucose most frequently indicates diabetes.
|
Baseline, 4 hours, 8 hours
|
Plasma Glucose Levels for Intralipid/Dextrose Infusion
Time Frame: Baseline, 4 hours, 8 hours
|
Blood samples were collected for measurement of plasma glucose levels at baseline, 4 hours after intralipid/dextrose infusion, and 8 hours after intralipid/dextrose infusion.
Plasma glucose was measured on CX7 Chemistry Analyzer.
Current guidelines identify normal fasting glucose as less than 100 mg/dL.
High levels of glucose most frequently indicates diabetes.
|
Baseline, 4 hours, 8 hours
|
Insulin Levels for Saline Infusion
Time Frame: Baseline, 4 hours, 8 hours
|
Blood samples were collected for the measurement of insulin levels at baseline, 4 hours after saline infusion, and 8 hours after saline infusion.
Insulin was measured in plasma using a solid phase, two-site sequential chemiluminescent immunometric assays on the DPC Immulite analyzer.
Current guidelines identify normal insulin levels as 8.8 μU/mL for men and 8.4 for women.
High levels of insulin most frequently indicate insulin resistance or hypoglycemia, if paired with a low glucose level.
Low levels of insulin paired with high glucose level can indicate diabetes.
|
Baseline, 4 hours, 8 hours
|
Insulin Levels for Intralipid Infusion
Time Frame: Baseline, 4 hours, 8 hours
|
Blood samples were collected for the measurement of insulin levels at baseline, 4 hours after intralipid infusion, and 8 hours after intralipid infusion.
Insulin was measured in plasma using a solid phase, two-site sequential chemiluminescent immunometric assays on the DPC Immulite analyzer.
Current guidelines identify normal insulin levels as 8.8 μU/mL for men and 8.4 for women.
High levels of insulin most frequently indicate insulin resistance or hypoglycemia, if paired with a low glucose level.
Low levels of insulin paired with high glucose level can indicate diabetes.
|
Baseline, 4 hours, 8 hours
|
Insulin Levels for Dextrose Infusion
Time Frame: Baseline, 4 hours, 8 hours
|
Blood samples were collected for the measurement of insulin levels at baseline, 4 hours after dextrose infusion, and 8 hours after dextrose infusion.
Insulin was measured in plasma using a solid phase, two-site sequential chemiluminescent immunometric assays on the DPC Immulite analyzer.
Current guidelines identify normal insulin levels as 8.8 μU/mL for men and 8.4 for women.
High levels of insulin most frequently indicate insulin resistance or hypoglycemia, if paired with a low glucose level.
Low levels of insulin paired with high glucose level can indicate diabetes.
|
Baseline, 4 hours, 8 hours
|
Insulin Levels for Intralipid/Dextrose Infusion
Time Frame: Baseline, 4 hours, 8 hours
|
Blood samples were collected for the measurement of insulin levels at baseline, 4 hours after intralipid/dextrose infusion, and 8 hours after intralipid/dextrose infusion.
Insulin was measured in plasma using a solid phase, two-site sequential chemiluminescent immunometric assays on the DPC Immulite analyzer.
Current guidelines identify normal insulin levels as 8.8 μU/mL for men and 8.4 for women.
High levels of insulin most frequently indicate insulin resistance or hypoglycemia, if paired with a low glucose level.
Low levels of insulin paired with high glucose level can indicate diabetes.
|
Baseline, 4 hours, 8 hours
|
C-peptides Levels for Saline Infusion
Time Frame: Baseline, 4 hours, 8 hours
|
Blood samples were collected for the measurement of C-peptide levels at baseline, 4 hours after saline infusion, and 8 hours after saline infusion. C-peptide was measured in plasma using a solid phase, two-site sequential chemiluminescent immunometric assays on the DPC Immulite analyzer. Current guidelines identify normal C-peptide levels as 0.51 to 2.72 ng/mL. A high level of C-peptide generally indicates a high level of endogenous insulin production. This may be in response to a high blood glucose caused by glucose intake and/or insulin resistance. A high level of C-peptide is also seen with insulinomas and may be seen with low blood potassium, Cushing syndrome, and renal failure. A low level of C-peptide is associated with a low level of insulin production. This can occur when insufficient insulin is being produced by the beta cells, with diabetes for example, or when production is suppressed by treatment with exogenous insulin. |
Baseline, 4 hours, 8 hours
|
C-peptides Levels for Intralipid Infusion
Time Frame: Baseline, 4 hours, 8 hours
|
Blood samples were collected for the measurement of C-peptide levels at baseline, 4 hours after Intralipid infusion, and 8 hours after Intralipid infusion. C-peptide was measured in plasma using a solid phase, two-site sequential chemiluminescent immunometric assays on the DPC Immulite analyzer. Current guidelines identify normal C-peptide levels as 0.51 to 2.72 ng/mL. A high level of C-peptide generally indicates a high level of endogenous insulin production. This may be in response to a high blood glucose caused by glucose intake and/or insulin resistance. A high level of C-peptide is also seen with insulinomas and may be seen with low blood potassium, Cushing syndrome, and renal failure. A low level of C-peptide is associated with a low level of insulin production. This can occur when insufficient insulin is being produced by the beta cells, with diabetes for example, or when production is suppressed by treatment with exogenous insulin. |
Baseline, 4 hours, 8 hours
|
C-peptides Levels for Dextrose Infusion
Time Frame: Baseline, 4 hours, 8 hours
|
Blood samples were collected for the measurement of C-peptide levels at baseline, 4 hours after dextrose infusion, and 8 hours after dextrose infusion. C-peptide was measured in plasma using a solid phase, two-site sequential chemiluminescent immunometric assays on the DPC Immulite analyzer. Current guidelines identify normal C-peptide levels as 0.51 to 2.72 ng/mL. A high level of C-peptide generally indicates a high level of endogenous insulin production. This may be in response to a high blood glucose caused by glucose intake and/or insulin resistance. A high level of C-peptide is also seen with insulinomas and may be seen with low blood potassium, Cushing syndrome, and renal failure. A low level of C-peptide is associated with a low level of insulin production. This can occur when insufficient insulin is being produced by the beta cells, with diabetes for example, or when production is suppressed by treatment with exogenous insulin. |
Baseline, 4 hours, 8 hours
|
C-peptides Levels for Intralipid/Dextrose Infusion
Time Frame: Baseline, 4 hours, 8 hours
|
Blood samples were collected for the measurement of C-peptide levels at baseline, 4 hours after intralipid/dextrose infusion, and 8 hours after intralipid/dextrose infusion. C-peptide was measured in plasma using a solid phase, two-site sequential chemiluminescent immunometric assays on the DPC Immulite analyzer. Current guidelines identify normal C-peptide levels as 0.51 to 2.72 ng/mL. A high level of C-peptide generally indicates a high level of endogenous insulin production. This may be in response to a high blood glucose caused by glucose intake and/or insulin resistance. A high level of C-peptide is also seen with insulinomas and may be seen with low blood potassium, Cushing syndrome, and renal failure. A low level of C-peptide is associated with a low level of insulin production. This can occur when insufficient insulin is being produced by the beta cells, with diabetes for example, or when production is suppressed by treatment with exogenous insulin. |
Baseline, 4 hours, 8 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00009277
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
Clinical Trials on Intralipid 20%
-
Indiana UniversityActive, not recruitingComparison of Smoflipid to Soy-based Lipid Reduction for Cholestasis Prevention in Surgical NeonatesCholestasis of Parenteral NutritionUnited States
-
Fresenius KabiTerminatedHospitalized Neonates and Infants, Expected to Require Parenteral Nutrition for 28 DaysUnited States
-
Fresenius KabiTerminatedMalnutrition, ChildUnited States
-
Woman's Health University Hospital, EgyptCompleted
-
Ain Shams UniversityRecruiting
-
Cairo UniversityCompleted
-
Emory UniversityAmerican Heart AssociationCompletedHypertension | Endothelial DysfunctionUnited States
-
Ain Shams UniversityUnknown
-
Methodist Research Institute, IndianapolisTerminatedAcute Respiratory Distress SyndromeUnited States
-
Nkanyiso HadebeUnknown